Holen Sie sich die Stockscreener-App
84.86
2.44%
-2.12
Handel nachbörslich:
84.95
0.09
+0.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program - The Globe and Mail
DexCom, Inc. (DXCM) Stock Analysis: 15.97% Potential Upside Amid Robust Analyst Support - DirectorsTalk Interviews
DexCom’s SWOT analysis: CGM leader faces supply challenges amid growth - Investing.com
DexCom: Non-Insulin Type 2 Diabetes Market Penetration Be A Breakthrough Move? - Smartkarma
An Intrinsic Calculation For DexCom, Inc. (NASDAQ:DXCM) Suggests It's 27% Undervalued - Yahoo Finance
Blood Glucose Monitoring (BGM) Devices Market Report 2025: Hospitals Lead in Blood Glucose Monitoring Device Usage, Home Care Grows Fastest - GlobeNewswire Inc.
DexCom (DXCM) Maintains Buy Rating as Price Target Raised to USD 102 | DXCM Stock News - GuruFocus
Citi Increases Price Target for DexCom (DXCM) to $102 | DXCM Stock News - GuruFocus
Diabetic Care Device Market Set for Significant Growth with 10.1% CAGR - GlobeNewswire Inc.
Dexcom (DXCM) Gets a Buy from Wells Fargo - The Globe and Mail
DexCom adds Renée Galá to Board of Directors By Investing.com - Investing.com Nigeria
3 Big Reasons to Love DexCom (DXCM) - Yahoo Finance
The End Of The Diabetes Industry?Eli Lilly (NYSE:LLY), DexCom (NASDAQ:DXCM) - Benzinga
FDA Approves DexCom G4 Platinum Professional Continuous Glucose Monitoring System - Medical Product Outsourcing
Can DexCom, Inc. (NASDAQ:DXCM) Maintain Its Strong Returns? - Yahoo Finance
Here's Why You Should Add DexCom Stock to Your Portfolio Now - MSN
Dexcom CEO says CGMs fit MAHA agenda ‘very nicely’; Tandem preps for new products - MedTech Dive
Is DexCom, Inc. (NASDAQ:DXCM) Trading At A 24% Discount? - simplywall.st
Do Wall Street Analysts Like DexCom Stock? - Nasdaq
DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook - Yahoo Finance
Dexcom Beats Investor Claims Over Sales Growth Potential for Now - Bloomberg Law News
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil - TradingView
Dexcom Beats Investor Claims Over Growth Potential for Now (1) - Bloomberg Law News
DexCom, Inc. (DXCM) Announces Leadership Promotion: Jacob S. Lea - GuruFocus
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO | DXCM Stock News - GuruFocus
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO - GuruFocus
DexCom (DXCM) Elevates Jake Leach to President - GuruFocus
Dexcom promotes Jake Leach to president role - MassDevice
The Zacks Analyst Blog Highlights Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx - TradingView
Dexcom Promotes Jake Leach to Expanded President, COO Role - Medical Product Outsourcing
DexCom Adds President Role to COO Jake Leach - marketscreener.com
All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy - Yahoo Finance
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns - TradingView
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case - MSN
DXCM STOCK NOTICE: Did DexCom, Inc. Commit Securities Fraud? Investors are Urged to Contact BFA Law about its Investigation if You Suffered Losses (DXCM) - ACCESS Newswire
Investor Network: DexCom, Inc. to Host Earnings Call - ACCESS Newswire
DexCom, Inc. (DXCM) Announces Key Approvals at Annual Meeting - GuruFocus
Shareholders of DexCom, Inc. Should Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - ACCESS Newswire
Dexcom Stockholders Approve Equity Plan Amendments - TipRanks
DXCM STOCK NOTICE: DexCom, Inc. Investors that Suffered Losses are Notified a Securities Fraud Investigation has been Initiated against DXCM and are Urged to Contact BFA Law - ACCESS Newswire
DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure (NASDAQ:DXCM) - Seeking Alpha
Should You Investigate DexCom, Inc. (NASDAQ:DXCM) At US$85.34? - Yahoo Finance
Is DexCom, Inc. (DXCM) the Best Medical Device Stock to Buy Now? - Insider Monkey
Shareholders that lost money on DexCom, Inc.(DXCM) should contact Levi & Korsinsky about pending Class ActionDXCM - ACCESS Newswire
Class Action Filed Against DexCom, Inc. (DXCM) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Lost Money on DexCom, Inc. (DXCM)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Shareholders that lost money on DexCom, Inc.(DXCM) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
DexCom, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - ACCESS Newswire
Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – DXCM - ACCESS Newswire
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):